Implication of protocadherin-PC in the progression of the advanced prostate cancer
Збережено в:
| Дата: | 2007 |
|---|---|
| Автори: | , , , , |
| Формат: | Стаття |
| Мова: | English |
| Опубліковано: |
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
2007
|
| Назва видання: | Experimental Oncology |
| Теми: | |
| Онлайн доступ: | http://dspace.nbuv.gov.ua/handle/123456789/138559 |
| Теги: |
Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|
| Назва журналу: | Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| Цитувати: | Implication of protocadherin-PC in the progression of the advanced prostate cancer / X. Giannakopoulos, D. Stagikas, D. Peschos, A. Batistatou, K. Charalabopoulos // Experimental Oncology. — 2007. — Т. 29, № 1. — С. 74-75. — Бібліогр.: 8 назв. — англ. |
Репозитарії
Digital Library of Periodicals of National Academy of Sciences of Ukraine| id |
irk-123456789-138559 |
|---|---|
| record_format |
dspace |
| spelling |
irk-123456789-1385592018-06-20T03:05:21Z Implication of protocadherin-PC in the progression of the advanced prostate cancer Giannakopoulos, X. Stagikas, D. Peschos, D. Batistatou, A. Charalabopoulos, K. Letter to editor 2007 Article Implication of protocadherin-PC in the progression of the advanced prostate cancer / X. Giannakopoulos, D. Stagikas, D. Peschos, A. Batistatou, K. Charalabopoulos // Experimental Oncology. — 2007. — Т. 29, № 1. — С. 74-75. — Бібліогр.: 8 назв. — англ. 1812-9269 http://dspace.nbuv.gov.ua/handle/123456789/138559 en Experimental Oncology Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України |
| institution |
Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| collection |
DSpace DC |
| language |
English |
| topic |
Letter to editor Letter to editor |
| spellingShingle |
Letter to editor Letter to editor Giannakopoulos, X. Stagikas, D. Peschos, D. Batistatou, A. Charalabopoulos, K. Implication of protocadherin-PC in the progression of the advanced prostate cancer Experimental Oncology |
| format |
Article |
| author |
Giannakopoulos, X. Stagikas, D. Peschos, D. Batistatou, A. Charalabopoulos, K. |
| author_facet |
Giannakopoulos, X. Stagikas, D. Peschos, D. Batistatou, A. Charalabopoulos, K. |
| author_sort |
Giannakopoulos, X. |
| title |
Implication of protocadherin-PC in the progression of the advanced prostate cancer |
| title_short |
Implication of protocadherin-PC in the progression of the advanced prostate cancer |
| title_full |
Implication of protocadherin-PC in the progression of the advanced prostate cancer |
| title_fullStr |
Implication of protocadherin-PC in the progression of the advanced prostate cancer |
| title_full_unstemmed |
Implication of protocadherin-PC in the progression of the advanced prostate cancer |
| title_sort |
implication of protocadherin-pc in the progression of the advanced prostate cancer |
| publisher |
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України |
| publishDate |
2007 |
| topic_facet |
Letter to editor |
| url |
http://dspace.nbuv.gov.ua/handle/123456789/138559 |
| citation_txt |
Implication of protocadherin-PC in the progression of the advanced prostate cancer / X. Giannakopoulos, D. Stagikas, D. Peschos, A. Batistatou, K. Charalabopoulos // Experimental Oncology. — 2007. — Т. 29, № 1. — С. 74-75. — Бібліогр.: 8 назв. — англ. |
| series |
Experimental Oncology |
| work_keys_str_mv |
AT giannakopoulosx implicationofprotocadherinpcintheprogressionoftheadvancedprostatecancer AT stagikasd implicationofprotocadherinpcintheprogressionoftheadvancedprostatecancer AT peschosd implicationofprotocadherinpcintheprogressionoftheadvancedprostatecancer AT batistatoua implicationofprotocadherinpcintheprogressionoftheadvancedprostatecancer AT charalabopoulosk implicationofprotocadherinpcintheprogressionoftheadvancedprostatecancer |
| first_indexed |
2025-07-10T06:03:23Z |
| last_indexed |
2025-07-10T06:03:23Z |
| _version_ |
1837238749365272576 |
| fulltext |
74 Experimental Oncology 29, 74–75, 2007 (March)
Dear Editor,
Prostate cancer is one of the most frequent dia
gnosed malignancies in men of Western Countries. This
tumor develops and progresses under the influence of
androgenic steroids. The basic molecular mechanisms
underlining the development and the progression of the
disease remains poorly described [1, 2]. However, many
research attempts exist concerning the identification of
potential genetic loci associated with familial forms of
prostate cancer [1, 3]. Nowadays, there is no radical
curative therapeutic approach for the advanced forms
of this pathological entity of the prostate gland. The
identification of the molecular mechanisms implied in the
neoplastic progression of the disease is thus of primary
importance for the development of new therapeutical
options [4]. Relatively recently, de la Taille et al. [5] and
Yang et al. [6] identified a new way of indication implied
in the acquisition of resistance concerning the hormonal
treatment of prostate cancer with the discovery and the
characterization of a new protocadherin, the protocadhe
rinPC. The expression of this molecular structure is
induced during the androgenic suppression [5, 6].
ProtocadherinPC is expressed in a preferential way by
the neoplastic cells of the hormonoresistant prostate
cancer. The increase in the form of the protocadherinPC
allows the tumor cells of the prostate cancer sufferers to
resist the apoptosis, to survive and proliferate in the total
absence of androgens. Indeed, the protocadherinPC
expression in a stable way by LNCaP cells, allow them
to proliferate and form soft agar colonies in a medium
impoverished of hormone as well as to form tumors in
the castrated mice nudes [5]. These data imply the role
of the protocadherinPC in the transition from the hor
monesensitivity of the LNCaP cells towards hormone
resistance. The study of its functions showed that the
protocadherinPC in addition, inhibits the transcription
activity of the receiver of the androgens by inducing its
degradation [6]. An abnormal distribution of the βcate
nin at the cytoplasmic and nuclear level in the cells with
selective expression the protocadherinPC (LNCaPTR
lines and — SSR), has been documented [5]. By the
transitory technique of transfection, it has been foundit has been found found
that protocadherinPC is directly implied in the modifica
tion of the intracellular distribution of the βcatenin [6]. Itβcatenin [6]. Itcatenin [6]. It
was clearly shown that accumulation of the βcatenin in
the cytoplasm of neoplastic cells supports its transloca
tion in the core and its connection with the transcription
factors of the Tcf/Lef family. These molecular complexes
are able to control the cellular proliferation of the tumor
cells and inhibit apoptosis by activating genes coding for
proteins like cmyc and of cycline D1 [7, 8]. It has been
also observed that the delocalization of the βcatenin by
the protocadherinPC supports the transcription activity
of the Tcf/Lef transcription factor in neoplastic prostate
cells. It is very interesting to note that the activation of
Tcf/Lef pathway by the protocadherinPC is observed
in other malignant cell lines. By using a chip of cDNA it
was demonstrated that the Wnt pathway is also activated
by protocadherinPC by inducing some members like
WNT3, 7B, 1 DA 11 and some receivers like FZD2, 4
and 10. In addition, increase in protocadherinPC also
leads to differentiation of the LNCaP cells to cells of
neuroendocrine phenotype. This transdifferentiation
induced by the protocadherinPC is abolished when the
neoplastic cells are treated with antiβcatenin siRNA or
with a antiLEF antisense vector showing thus, that this
process of transdifferentiation is an associated activation
of the Wnt pathway [6]. In conclusion, experimental stu
dies show the implication of the protocadherinPC in the
progression of the prostate cancer. Thus, this protein rep
resents a target for the treatment of this malignancy.
RefeRences
1. Bratt O, Damber JE, Emanuelsson M, Gronberg H.
Hereditary prostate cancer: clinical characteristics and survival.
J Urol 2002; 167: 2423–6.
2. Giannakopoulos X, Baltogiannis D, Charalabopoulos K,
Sofikitis N. Monotherapy in advanced prostate cancer. An
overview. Exp Oncol 2004; 26: 185–91.
3. Vastag B. Genome analysis yields mutations linked to
hereditary prostate cancer. JAMA 2002; 287: 827–8.
4. Chen MW, Vacherot F, de la Taille A, Gil-Diez-De-
Medina S, Shen R, Friedman RA, Burchardt M, Chopin DK,
Buttyan R. The emergence of protocadherin-PC expression
during the acquisition of apoptosis-resistance by prostate
cancer cells. Oncogene 2002; 21: 7861–71.
5. de la Taille A, Rubin MA, Chen MW, Vacherot F, de Me-
dina SG, Burchardt M, Buttyan R, Chopin D. Buttyan R, Chopin D.Buttyan R, Chopin D. Beta-catenin-re-
lated anomalies in apoptosis-resistant and hormone-refractory
prostate cancer cells. Clin Cancer Res 2003; 9: 1801–7.
6. Yang X, Chen MW, Terry S, Vacherot F, Chopin DK,
Bemis DL, Kitajewski J, Benson MC, Guo Y, Buttyan R.
A human- and male-specific protocadherin that acts through
the wnt signalling pathway to induce neuroendocrine
transdifferentiation of prostate cancer cells. Cancer Res 2005;
65: 5263–71.
IMPLIcATIOn Of PROTOcADHeRIn-Pc In THe PROGRessIOn
Of THe ADVAnceD PROsTATe cAnceR
X. Giannakopoulos1, �. ��a�ikas�. ��a�ikas2, �. ��s��os�. ��s��os3, A. Ba�is�a�ou3, K. C�aralabopoulos2, *
1Department of Urology, Medical Faculty, University of Ioannina, Ioannina, Greece
2Department of Physiology, Medical Faculty, University of Ioannina, Ioannina, Greece
3Department of Pathology, Medical Faculty, University of Ioannina, Ioannina, Greece
Received: January 28, 2007.
*Correspondence: �a�: ��0 2���0 �78�0�a�: ��0 2���0 �78�0
E-mail: kcharala@cc.uoi.gr
Exp Oncol 2007
29, 1, 74–75
LeTTeR TO THe eDITOR
Experimental Oncology 29, 74–75, 2007 (March) 7529, 74–75, 2007 (March) 75March) 75) 75 75
7. Korinek V, Barker N, Morin PJ, van Wichen D, de We-
ger R, Kinzler KW, Vogelstein B, Clevers H.Vogelstein B, Clevers H. Constitutive
transcriptional activation by a beta-catenin-Tcf complex in
APC-/-colon carcinoma. �cience 1997;colon carcinoma. �cience 1997; �cience 1997;�cience 1997; 275: 1784–7.
8. Chen S, Guttridge DC, You Z, Zhang Z, Fribley A,
Mayo MW, Kitajewski J, Wang CY.CY. Wnt-1 signaling inhibits
apoptosis by activating beta-catenin/T cell factor-mediated
transcription. J Cell Biol 2001; 152: 87–96.
Copyright © E�perimental Oncology, 2007
|